Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02400190 · ClinicalTrials.gov registry record · NA
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
A NA study of Breast Neoplasms, sponsored by University of Michigan Rogel Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 202
- Enrollment target
- 13
- Study locations
NCT02400190 is a NA study of Breast Neoplasms that is active but no longer recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 202 participants, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (64% lower). The trial reports 13 study locations across 12 states.
The verdict
NCT02400190, a NA study of Breast Neoplasms, is active but no longer recruiting, sponsored by University of Michigan Rogel Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 202 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.
Conditions Studied
Interventions
- OTHER endocrine therapy alone without radiotherapy
Study Locations (13)
New York
- Northwell Health - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
California
- Stanford University - Stanford
Connecticut
- Yale University - New Haven
Illinois
- Loyola University Medical Center - Maywood
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Harvard University - Cambridge
Michigan
- University of Michigan - Ann Arbor
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2015-05-27 |
| Est. Completion | 2026-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02400190
The ClinicalTrials.gov registry entry for NCT02400190 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (64% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which endocrine therapy alone without radiotherapy is the first listed.
NCT02400190 reports 13 study locations spanning 12 distinct geographic areas - top geographies include New York, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02400190 about?
NCT02400190 is a clinical study titled "The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)". This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive e...
What is the current status of trial NCT02400190?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 202 participants. The study started on 2015-05-27. Estimated completion is 2026-05.
What conditions does trial NCT02400190 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT02400190?
The interventions under investigation include: endocrine therapy alone without radiotherapy (OTHER).
Who is sponsoring clinical trial NCT02400190?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02400190 being conducted?
This trial has 13 study locations across California, Connecticut, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Breast Cancer, Reasoning, and Activity Intervention
RECRUITING · NA
-
Biennial CEM in Women With a Personal History of Breast Cancer
RECRUITING · NA
-
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
RECRUITING · NA
-
Dissemination of BREASTChoice AIM1-B
RECRUITING · NA
-
Lifestyle, Exercise, and Nutrition Study Early After Diagnosis
ACTIVE NOT RECRUITING · NA
-
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.